Fluorinex Active Ltd.

www.fluorinex.co.il

High-Tech Company

Acquired by Candela Medical

Graduated from: NGT

TECH VERTICALS

Healthtech, Life Sciences, Medical Devices, MedTech, Therapeutics

General Data

Sector	Medical Devices
Company Stage:	R&D
Established	2004
Number of Employees	5
Reg. Number:	abCDe

DESCRIPTION

Fluorinex developed a revolutionary tooth decay and dental caries prevention method and device. Fluorinex mission is to prevent the debilitating disease of caries and eliminate tooth decay in human beings in a similar way that immunization and vaccines eradicated many other diseases.

TECHNOLOGY

Given the notion that fluoride has a major role in fighting dental caries, it is Fluorinex main goal to adhere as much fluor ions to the tooth enamel, since this is the location where it is most needed and is where its action is the most efficient.

Fluoride-enriched gels can provide the much needed protection to some extent, through teeth immersion. However, it can be shown that such protection has a very limited endurance.

Fluorinex technology is based on the same fluoride-enriched gels. The device is a dental fluoride tray with an added feature which allows for more efficient release of the fluoride from the gel contained in the tray. The tray units are each equipped with small implanted electrodes (one electrode at each end/side of the upper and lower trays) through which a low voltage current (circa 6-9 volt, at low amperage) can be introduced into the fluoride gel contained in the tray, resulting in a current flow through the fluoride gel. The current source can be a battery or a low voltage DC power supply. Fluorinex's research and development effort has established that such application of a small current to the fluoride gel in a fluoride gel dental tray increases the effectiveness of release of fluoride from the gel, thereby increasing the delivery of fluoride to the tooth enamel per unit of treatment time. The Fluorinex "enhanced fluoride delivery" dental tray is expected to function with any fluoride gel currently approved in the United States or Europe provided that the gel composition will support a current flow.

Because both positive and negative electrodes are within the gel when energized and are a part of the tray itself, there is no passage of the current circuit through the patient’s body. That is, current flow is only through the gel in the tray.

This operating principle differs from previously proposed “iontophoretic” fluoride delivery systems. In such systems (which are not approved in the U.S. and which have been found by various investigators not to provide for any enhancement of fluoride delivery) a current is passed between a metal fluoride tray (which acts as one electrode) and a second electrode affixed to the patient’s body. In such a configuration current clearly passes through the patient's tissues - - a critical characteristic of any iontophoresis device (iontophoresis functions by passing a direct voltage current through some portion of a patient’s body with the intent of introducing ions of soluble salts or other drugs into the body. Fluorinex’s fluoride tray is clearly not an iontophoresis system as: (a) in the Fluorinex system no current is passed through the patient’s body; and, therefore, (b) the fluoride released from the gel in the tray is not driven into the body (the teeth in this case) by any current flow passing into the body through the teeth.

The teeth are kept at positive polarity throughout the entire procedure. The positively charged teeth attract a significant amount of fluor ions that adhere onto the tooth enamel. This feature is the breakthrough innovation that enables the significantly higher effectiveness of Fluorinex's procedure.

Products and Phases

Product	Phase
Flurinex	CE Approved
A device for long term protection against dental caries

	TARGET MARKETS
	Dentists, Consumers, Pharma companies.

	BUSINESS MODEL
	B2C

CONTACT INFO

Expand / Collapse All

Main Address: Yoqneam, Israel

Address	Yokneam Industrial Zone, Tavor Bldg., Entrance # 3, 3rd Level
POB	43
City	Yoqneam
Country	Israel
Zip	20692

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Kamal Khawalled	Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Founder, Syneron
abC Defghij	Board Member	VP Sales, Syneron

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Jun. 01, 2009

abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

First Round

Apr. 10, 2008

R&D

abCDe

Seed

Jan. 18, 2004

Seed

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jan. 18, 2004

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

Last Updated:	abCDe
IVC Number:	abCDe